Qpex Biopharma
Qpex Biopharma Inc., a Shionogi Group Company, is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel anti-infective therapies. Their focus is on addressing antimicrobial resistance through innovative drug discovery, including their lead program based on xeruborbactam, a beta-lactamase inhibitor. The company leverages decades of expertise in drug resistance mechanisms and collaborates with government, academia, and industry to meet unmet medical needs in infectious diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Clinical-stage investigational boronate beta-lactamase inhibitor (IV and oral prodrug development)
A clinical-stage boronate-class beta-lactamase inhibitor developed to inhibit a broad spectrum of serine and metallo-beta-lactamases and restore activity of beta-lactam antibiotics in resistant Gram-negative pathogens; being advanced in intravenous combinations and an oral prodrug formulation.
Synthetic lipopeptide antibiotic candidate targeting multidrug-resistant Gram-negative pathogens
A synthetic lipopeptide antibiotic program developed to target multidrug-resistant Gram-negative bacteria; data published in a peer-reviewed journal and advanced through preclinical and early clinical evaluation.
Xeruborbactam + Ceftibuten
S-743229 is an investigational combination of the beta-lactamase inhibitor xeruborbactam with ceftibuten, designed as an oral antibacterial therapy for settings where intravenous therapy is not possible or desirable.
Xeruborbactam + Cefiderocol
An investigational combination therapy focusing on infections due to Gram-negative bacteria delivered via intravenous infusion.
S-649228
An investigational compound in the R&D pipeline aimed at addressing serious current and emerging Gram-negative bacterial infections.
Clinical-stage investigational boronate beta-lactamase inhibitor (IV and oral prodrug development)
A clinical-stage boronate-class beta-lactamase inhibitor developed to inhibit a broad spectrum of serine and metallo-beta-lactamases and restore activity of beta-lactam antibiotics in resistant Gram-negative pathogens; being advanced in intravenous combinations and an oral prodrug formulation.
Synthetic lipopeptide antibiotic candidate targeting multidrug-resistant Gram-negative pathogens
A synthetic lipopeptide antibiotic program developed to target multidrug-resistant Gram-negative bacteria; data published in a peer-reviewed journal and advanced through preclinical and early clinical evaluation.
Xeruborbactam + Ceftibuten
S-743229 is an investigational combination of the beta-lactamase inhibitor xeruborbactam with ceftibuten, designed as an oral antibacterial therapy for settings where intravenous therapy is not possible or desirable.
Xeruborbactam + Cefiderocol
An investigational combination therapy focusing on infections due to Gram-negative bacteria delivered via intravenous infusion.
S-649228
An investigational compound in the R&D pipeline aimed at addressing serious current and emerging Gram-negative bacterial infections.
Services
Strategic partnerships with government, academia and industry to advance anti-infective discovery and development programs.
Strategic partnerships with government, academia and industry to advance anti-infective discovery and development programs.
Expertise Areas
- Anti-infective drug discovery
- Beta-lactamase inhibitor development
- Microbiology and resistance mechanism characterization
- Translational pharmacology (PK/PD)
Key Technologies
- Boron-based medicinal chemistry
- X-ray co-crystallography / structural biology
- Enzyme inhibition assays
- In vitro antimicrobial susceptibility testing (MIC panels)